Role of prophylactic add on tranexamic acid in active management of third stage of labour: a prospective randomised study

Shubhra Aggarwal; Tanushree Jain; Akash Jain; Ratna T. Papola

doi:10.18203/2320-1770.ijrcog20262553

Authors

Shubhra Aggarwal Department of Obstetrics and Gynecology, Teerthankar Mahaveer Medical College and Research Centre, Moradabad, Uttar Pradesh, India
Tanushree Jain Department of Obstetrics and Gynecology, Teerthankar Mahaveer Medical College and Research Centre, Moradabad, Uttar Pradesh, India
Akash Jain Department of Obstetrics and Gynecology, Teerthankar Mahaveer Medical College and Research Centre, Moradabad, Uttar Pradesh, India
Ratna T. Papola Department of Obstetrics and Gynecology, Teerthankar Mahaveer Medical College and Research Centre, Moradabad, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20262553

Keywords:

Tranexamic acid, Postpartum haemorrhage, Active management of third stage of labour, Oxytocin, Antifibrinolytic, Maternal mortality, Fibrinolysis

Abstract

Background: Postpartum haemorrhage (PPH) remains the leading cause of maternal mortality worldwide. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent, and its established efficacy in reducing haemorrhage in trauma and surgical contexts. Its prophylactic use in the obstetric setting is of growing interest. This study aims to evaluate the efficacy and safety of prophylactic TXA (1 g intravenous) as an adjunct to oxytocin (10 IU intramuscular) in reducing postpartum blood loss and the incidence of PPH for active management of third stage of labour in women undergoing vaginal delivery.

Methods: A prospective, double-blind, randomized controlled trial was conducted at a tertiary care teaching hospital, over 18 months. Eligible women with singleton pregnancies at ≥37 weeks of gestation expecting vaginal delivery were randomized 1:1 to group A (TXA 1 g IV slow infusion + oxytocin 10 IU IM; n=78) or Group B (normal saline 10 ml IV + oxytocin 10 IU IM; n=78). Primary endpoints were total measured postpartum blood loss (ml) and incidence of PPH (≥500 ml). Secondary endpoints included reduction in level of haemoglobin at 24 hours, requirement for additional uterotonics, blood transfusion requirement, duration of third stage, adverse maternal effects, and neonatal outcomes.

Results: Mean postpartum blood loss was significantly lower in group T than group O (72.56±30.94 ml versus 72.82±25.73 ml; p<0.05). PPH incidence was significantly reduced in the TXA group (8.97% versus 28.20%; OR: [0.25], RR: [0.32], 95% CI [0.14–0.70]; NNT=[6]; p<0.05). Mean haemoglobin fall, need for additional uterotonics, and blood transfusion rate were all significantly lower in group T. No significant difference in adverse effects, thromboembolic events, or neonatal outcomes was observed between groups.

Conclusions: Prophylactic TXA 1 g iv as an adjunct to standard therapy significantly reduces postpartum blood loss and PPH incidence without increasing adverse maternal or neonatal outcomes.

References

World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. 2012. Available at: https://www.who. int/publications/i/item/9789241548502. Accessed on 12 May 2026.

Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323-33.

Ministry of Health and Family Welfare, Government of India. Operational guidelines for maternal and newborn health. 2014. Available at: https://www. nhsrcindia.org/sites/default/files/2021-04/Operationa l%20Guidelines%20for%20Maternal%20Newborn%20Health.pdf. Accessed on 12 May 2026.

Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57:1005-32.

Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054.

CRASH-2 Trial Collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23-32.

Shakur H, Roberts I, Fawole B, Chaudhri R, El-Sheikh M, Akintan A, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389:2105-16.

Gungorduk K, Asicioglu O, Yildirim G, Aslan H, Gulkilik A, Ark C. Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. Am J Perinatol. 2013;30:407-13.

Mirghafourvand M, Mohammad-Alizadeh-Charandabi S, Ahmadpour P, Javadzadeh Y. Effects of prophylactic tranexamic acid on haemorrhage and maternal outcomes after vaginal delivery: a randomised clinical trial. J Matern Fetal Neonatal Med. 2016;29:3673-9.

Sentilkumar G, Priya PP, Shanthi V. Tranexamic acid in active management of third stage of labour. J Obstet Gynaecol India. 2016;66:S96-101.

Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2015;6:CD007872.

Reichman O, Yousef A, Margaliot T, Lando MB, Helman S, Plotkin V, et al. Tranexamic acid in the management of postpartum hemorrhage following vacuum-assisted vaginal delivery in primiparous women: a retrospective cohort study. BMC Pregnancy Childbirth. 2025;25:1-7.

Sahu J, Mishra N. Role of intravenous tranexamic acid in reducing blood loss during caesarean section: study at tribal-dominated area hospital in Chhattisgarh, India. J Obstet Gynaecol Res. 2019;45:841-8.

Arya P, Yadav G, Singh P, Ghuman NK, Sharma C, Gothwal M, et al. Tranexamic acid in preventing postpartum blood loss in vaginal delivery: a double-blinded randomized controlled trial. Am J Obstet Gynecol MFM. 2024;6:101450.

Kodan LR, Verschueren KJC, Prüst ZD, Zuithoff NPA, Rijken MJ, Browne JL, et al. Postpartum hemorrhage in Suriname: a national descriptive study of hospital births and an audit of case management. PLoS One. 2020;15:e0244087.

Omoronyia EE, Ekuma MI, Eyong E, Abeshi SE, Akpan UB. Effect of prophylactic tranexamic acid on peripartum changes in haemoglobin concentration after vaginal delivery. Sultan Qaboos Univ Med J. 2025;25:363-9.

World Health Organization. WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage. 2017. Available at: https://www.who. int/publications/i/item/WHO-RHR-17.21. Accessed on 12 May 2026.

Gohel M, Patel P, Gupta A, Desai P. Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section: a randomized case controlled prospective study. J Obstet Gynecol India. 2007;57:227-30.

Lecker I, Wang D, Whissell PD, Avramescu S, Mazer CD, Orser BA. Tranexamic acid-associated seizures: causes and treatment. Ann Neurol. 2016;79:18-26.